HLB Group: Chairman Jin Yang-gon buys shares in HLB Zenith
Predicted impact: Low· Actual: −1.7% vs sector, volume 1.0× normal (5 trading days)
Chairman's routine affiliate share purchases; repeated pattern of buying already reported.
HLB GenexHLB제넥스
187420 · KOSDAQ · ₩187420 · HLB제넥스
₩2,255▼ ₩45 (1.96%)End-of-day · Oct 29, 2026 · End-of-day prices.
Price · 1Y −27.14%
- Market cap
- ₩74B
- Enterprise value
- ₩79B
- P/E
- 7.9×
- P/B
- 1.4×
- Dividend yield
- 0.0%
- ROE
- 17.2%
- Net margin
- 20.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−38.7% from the high
₩1,323Today: ₩2,190 – ₩2,295₩3,680
Returns
- 1W−2.8%
- 1M+10.8%
- 3M+64.2%
- 6M−23.3%
- YTD−14.9%
- 1Y−27.1%
- Volume today
- 123,698
- 0.2× the 20-day average
- Traded today
- ₩278M
- Listed shares
- 32,651,437
- EPS (12 months)
- ₩284
- Earnings yield 12.6%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 25 of 100 (50 is a normal day for this stock).
- MomentumFlat-2.8% over the last month; the price is above its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
HLB Genex stock overview
HLB Genex (HLB제넥스, KRX: 187420) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops and manufactures custom enzymes and bio-healthcare materials, and is developing microbiome-based enzyme products. Its shares closed at ₩2,255 on Oct 29, 2026, down 1.96% on the day, giving it a market value of ₩74B.
Key facts
- Market cap
- ₩74B
- Sector
- Biotech & Pharma
- Latest price change
- −1.96%
- As of
- Oct 29, 2026
- Main business
- The company develops and manufactures custom enzymes and bio-healthcare materials, and is developing microbiome-based enzyme products.
Quick answers about HLB Genex
- What does HLB Genex do?
- The company develops and manufactures custom enzymes and bio-healthcare materials, and is developing microbiome-based enzyme products. Its core platform technologies include microbial display and recombinant protein secretion expression, covering the full enzyme development and production cycle. Its main products include industrial enzymes such as catalase for semiconductor and textile processing, lactase for producing galactooligosaccharides, and bio-healthcare materials such as phytosphingosine, menaquinone-7 (vitamin K2), and N-acetylphytosphingosine for cosmetics and dietary supplements, with a subsidiary developing brain nervous system disease drug candidates.
- What is the market cap of HLB Genex?
- The market capitalisation of HLB Genex was ₩74B at the close on Oct 29, 2026.
- Who are the largest shareholders of HLB Genex?
- According to the latest official filings, the largest reported holders are HLB (39.10%, as of Oct 15, 2026); Ban Jae-gu (6.44%, as of Jul 20, 2026); Kim Ui-jung (3.75%, as of Jan 15, 2026).
- When is the next earnings report from HLB Genex?
- Korean companies rarely announce results dates in advance. Based on when HLB Genex filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company develops and manufactures custom enzymes and bio-healthcare materials, and is developing microbiome-based enzyme products. Its core platform technologies include microbial display and recombinant protein secretion expression, covering the full enzyme development and production cycle. Its main products include industrial enzymes such as catalase for semiconductor and textile processing, lactase for producing galactooligosaccharides, and bio-healthcare materials such as phytosphingosine, menaquinone-7 (vitamin K2), and N-acetylphytosphingosine for cosmetics and dietary supplements, with a subsidiary developing brain nervous system disease drug candidates.
Written by AI from the company's latest annual report.
- Korean name
- HLB제넥스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김의중, 김도연 (각자 대표이사)
- Founded
- Mar 2000
- Listed
- May 2015
- Listed shares
- 32,651,437
- Fiscal year ends
- Month 12
- Website
- www.genofocus.com
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent news
Chairman Jin Yang-gon of HLB keeps buying affiliate shares; Epoch expands HLB Genex stake
Predicted impact: Low· Actual: −1.7% vs sector, volume 1.0× normal (5 trading days)
Chairman's affiliate share purchases repeat recent holding reports.
HLB Chairman Jin Yang-gon buys more HLB Genex shares — 62 purchases of affiliate stock under personal name
Predicted impact: Low· Actual: −1.7% vs sector, volume 1.0× normal (5 trading days)
Chairman's continued affiliate share buying; the stake news was already reported recently.
Recent filings
See all- 5%+ holding reportOct 15, 2026
- Investor relations (IR) eventOct 12, 2026
- 5%+ holding reportSep 17, 2026
- Insider shareholding reportSep 17, 2026
- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) After Issuance and Before MaturitySep 14, 2026
Titles in Korean until English translations are added.
Also known as: HLB Genex / HLB제넥스 / 187420 / KRX:187420
Source: KRX statistical information